Skip to Content

Join the 'Ixinity' group to help and get support from people like you.

Ixinity News

Emergent BioSolutions Announces FDA Approval of Ixinity [coagulation factor IX (recombinant)] for Hemophilia B

Posted 1 May 2015 by Drugs.com

GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Ixinity [coagulation factor IX (recombinant)], an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children, ≥12 years of age, with Hemophilia B. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding. "Emergent is committed to making a positive impact on the Hemophilia B community, including people living with this chronic bleeding disorder as well as their families, caregivers, and healthcare providers," said Barry Labinger, Executive Vice President and President, Biosciences Division at Emergent B ... Read more

Related support groups: Hemophilia B, Coagulation Factor Ix, Ixinity

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia B

Ixinity Patient Information at Drugs.com